Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5636175 | 0.91 | KCNH2 (0.48) | KCNH2BRAFSLC2A1MAP4K4 | |
| SCHEMBL5260294 | 0.91 | KCNH2 (0.48) | KCNH2BRAFSLC2A1MAP4K4 | |
| SCHEMBL5636821 | 0.86 | KCNH2 (0.57) | KCNH2BRAFSLC2A1MAP4K4 | |
| SCHEMBL5530317 | 0.80 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL4510826 | 0.79 | KCNH2 (0.42) | KCNH2MAP4K4 | |
| SCHEMBL4772967 | 0.78 | KCNH2 (0.48) | KCNH2MAP4K4 | |
| SCHEMBL633007 | 0.77 | KCNH2 (0.50) | KCNH2MAP4K4 | |
| SCHEMBL3577434 | 0.77 | PLAU (0.44) | KCNH2BRAF | |
| SCHEMBL3577439 | 0.77 | PLAU (0.44) | KCNH2BRAF | |
| SCHEMBL4271556 | 0.76 | ATM (0.45) | KCNH2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
| US-20060189604-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189604-A1 | Compounds | ELANE, PIGS, SDHA | KCNH2 2854/4885BRAF 2178/4885SLC2A1 3193/4885 |
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | KCNH2 3731/4885BRAF 3659/4885SLC2A1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.